1. Home
  2. FOLD vs DEI Comparison

FOLD vs DEI Comparison

Compare FOLD & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • DEI
  • Stock Information
  • Founded
  • FOLD 2002
  • DEI 1971
  • Country
  • FOLD United States
  • DEI United States
  • Employees
  • FOLD 499
  • DEI N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • DEI Real Estate Investment Trusts
  • Sector
  • FOLD Health Care
  • DEI Real Estate
  • Exchange
  • FOLD Nasdaq
  • DEI Nasdaq
  • Market Cap
  • FOLD 2.5B
  • DEI 2.6B
  • IPO Year
  • FOLD 2007
  • DEI 2006
  • Fundamental
  • Price
  • FOLD $8.42
  • DEI $13.16
  • Analyst Decision
  • FOLD Strong Buy
  • DEI Hold
  • Analyst Count
  • FOLD 9
  • DEI 8
  • Target Price
  • FOLD $26.44
  • DEI $17.86
  • AVG Volume (30 Days)
  • FOLD 5.3M
  • DEI 1.8M
  • Earning Date
  • FOLD 11-05-2025
  • DEI 11-04-2025
  • Dividend Yield
  • FOLD N/A
  • DEI 5.68%
  • EPS Growth
  • FOLD N/A
  • DEI N/A
  • EPS
  • FOLD N/A
  • DEI 0.22
  • Revenue
  • FOLD $571,160,000.00
  • DEI $1,001,173,000.00
  • Revenue This Year
  • FOLD $21.04
  • DEI $2.92
  • Revenue Next Year
  • FOLD $21.34
  • DEI $1.96
  • P/E Ratio
  • FOLD N/A
  • DEI $61.72
  • Revenue Growth
  • FOLD 25.35
  • DEI 3.24
  • 52 Week Low
  • FOLD $5.51
  • DEI $12.39
  • 52 Week High
  • FOLD $12.65
  • DEI $20.50
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 57.84
  • DEI 19.97
  • Support Level
  • FOLD $7.87
  • DEI $13.62
  • Resistance Level
  • FOLD $8.49
  • DEI $13.98
  • Average True Range (ATR)
  • FOLD 0.37
  • DEI 0.36
  • MACD
  • FOLD -0.03
  • DEI -0.20
  • Stochastic Oscillator
  • FOLD 81.67
  • DEI 1.29

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.

Share on Social Networks: